Charles Schwab Investment Management Inc. Has $444.83 Million Stake in Boston Scientific Co. (NYSE:BSX)

Charles Schwab Investment Management Inc. grew its stake in shares of Boston Scientific Co. (NYSE:BSX) by 0.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 7,694,726 shares of the medical equipment provider’s stock after buying an additional 51,892 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.53% of Boston Scientific worth $444,832,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. raised its stake in shares of Boston Scientific by 5.6% in the 3rd quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock valued at $27,353,000 after buying an additional 27,620 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in Boston Scientific in the fourth quarter worth about $5,116,000. Glenmede Trust Co. NA lifted its stake in Boston Scientific by 12.1% during the third quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock worth $551,000 after purchasing an additional 1,123 shares during the period. Principal Financial Group Inc. boosted its holdings in Boston Scientific by 2.1% during the third quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider’s stock valued at $98,683,000 after purchasing an additional 38,249 shares in the last quarter. Finally, HealthInvest Partners AB acquired a new position in shares of Boston Scientific in the 4th quarter worth approximately $3,746,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the transaction, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total value of $899,779.32. Following the completion of the sale, the chief financial officer now directly owns 271,542 shares in the company, valued at $17,883,756.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 17,587 shares of Boston Scientific stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total value of $1,257,470.50. Following the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,620,617. The disclosure for this sale can be found here. Insiders have sold 78,384 shares of company stock worth $5,395,560 in the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 1.2 %

NYSE:BSX traded up $0.88 during mid-day trading on Tuesday, hitting $73.43. The company had a trading volume of 4,151,495 shares, compared to its average volume of 6,613,376. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $74.39. The firm has a market cap of $107.73 billion, a P/E ratio of 61.71, a P/E/G ratio of 2.51 and a beta of 0.77. The business’s fifty day moving average is $68.68 and its two-hundred day moving average is $61.74.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Robert W. Baird boosted their price target on Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Royal Bank of Canada boosted their target price on shares of Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Evercore ISI increased their target price on shares of Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.